Employees: 1,114
Size Kaken Pharmaceutical (4521.T) is a Japan Health Care company (Pharmaceuticals: Major) with a market value of $860M, the 810th largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥3,815 on 18 Nov 2026.
Performance Over six months the shares fell 8.1%, against -22.8% for the median peer and -1.4% for the Japan market (cap-weighted) — 6th highest of 19 in its peer set.
Growth Revenue grew 5.4% over the last twelve months (peer median +1.7%); the operating margin is 10.5% (peer median 1.4%).
Valuation It trades at 21.4× forward earnings against a peer median of 28.1× (4th cheapest of 8).
Capital Return on invested capital runs 1.4 points above its cost of capital (5.0% WACC).
Next results Next results expected around 4 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ¥86.5B | ¥76.9B | ¥94.0B | ¥72.0B | ¥73.0B |
| Revenue growth | — | -18% | +31% | -1% | — |
| Gross profit | ¥49.2B | ¥39.2B | ¥58.3B | ¥38.2B | ¥39.3B |
| EBITDA | ¥13.0B | ¥2.43B | ¥23.6B | ¥12.3B | ¥10.6B |
| Net income | ¥9.15B | ¥2.14B | ¥13.9B | ¥8.03B | ¥5.44B |
| Free cash flow | n/a | -¥14.1B | ¥25.6B | ¥716M | ¥7.27B |
| Capital expenditure | n/a | ¥5.72B | ¥4.66B | ¥2.17B | ¥2.21B |
| Total debt | ¥4.55B | ¥3.94B | ¥3.96B | ¥3.85B | ¥3.85B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 4521.T | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +0.1% | -10.5% | 4th highest of 21 |
| 6-month return | -8.1% | -22.8% | 6th highest of 19 |
| Distance from 52-week high | -14.2% | -42.6% | 2nd highest of 21 |
| Revenue growth (TTM) | +5.4% | +1.7% | 9th highest of 19 |
| Operating margin | 10.5% | 1.4% | 4th highest of 19 |
| Forward P/E | 21.4× | 28.1× | 4th cheapest of 8 |
| ROIC minus cost of capital | +1.4 pp | -3.5 pp | 6th highest of 16 |
| EV / EBITDA | 6.3× | 9.9× | cheapest of 7 |
| Net debt / EBITDA | -4.2× | 0.7× | least indebted of 7 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Kaken Pharmaceutical 4521.T | Japan | $860M | -8% | +5% | 10% | 21.4× | n/a | n/a |
| City Therapeutics CTY | United States | $861M | n/a | +388% | -442% | n/a | n/a | n/a |
| Corvus Pharmaceuticals CRVS | United States | $860M | -16% | n/a | n/a | n/a | n/a | n/a |
| Daewoong Pharm 069620.KS | South Korea | $856M | -33% | +9% | 12% | 9.0× | n/a | n/a |
| DongKook Pharmaceutical 086450.KS | South Korea | $855M | +9% | +13% | 10% | 14.0× | -4.2% | +10.6% |
| GuangYuYuan Chinese Herbal Medicine 600771.SS | China | $866M | -26% | -6% | 5% | 38.3× | 31.7% | +4.2% |
| SK Discovery 006120.KS | South Korea | $866M | +25% | +24% | 3% | n/a | n/a | n/a |
| Jiangsu Yahong Meditech 688176.SS | China | $854M | -20% | +15% | -172% | n/a | n/a | n/a |
| Pharming PHARM.AS | Netherlands | $867M | -6% | +2% | 9% | 34.9× | 2.4% | +12.4% |
| Sanofi Consumer Healthcare India SANOFICONR.NS | India | $869M | -26% | +23% | 36% | 28.1× | 17.7% | +22.7% |
| Beijing Sun-Novo Pharmaceutical Research 688621.SS | China | $849M | -8% | -1% | -2% | 29.0× | n/a | n/a |
| Latigo Biotherapeutics LTGO | United States | $882M | n/a | n/a | n/a | n/a | n/a | n/a |
| Hunan Er-Kang Pharmaceutical 300267.SZ | China | $829M | -40% | -14% | -29% | n/a | n/a | n/a |
| Northeast Pharmaceutical 000597.SZ | China | $895M | -14% | -6% | 3% | n/a | -7.6% | -0.7% |
| Aktis Oncology AKTS | United States | $895M | -15% | +337% | -837% | n/a | n/a | n/a |
| Dezhan Healthcare 000813.SZ | China | $825M | -33% | -10% | -121% | n/a | n/a | n/a |
| Zhejiang Ausun Pharmaceutical 603229.SS | China | $824M | -34% | +1% | 0% | n/a | n/a | n/a |
| Wanbangde Pharmaceutical 002082.SZ | China | $823M | -52% | -38% | -10% | n/a | 27.7% | -39.5% |
| Sichuan Huiyu Pharmaceutical 688553.SS | China | $904M | -28% | +14% | 7% | n/a | 19.4% | -6.0% |
| Genfleet Therapeutics (Shanghai) 2595.HK | Hong Kong | $912M | -42% | -55% | -457% | n/a | n/a | n/a |
| Hygeia Healthcare 6078.HK | Hong Kong | $811M | -3% | +2% | 14% | 10.4× | 4.6% | +22.5% |